ANGel is an innovative platform technology developed to overcome the disadvantages of existing immune-oncology drugs, specifically their low deliverability, efficacy, and sustainability.
- High Deliverability: It contains over 90% water, making it highly malleable and capable of being injected subcutaneously directly into solid tumor sites. While traditional chemotherapy drugs are delivered through the bloodstream and can affect both cancer and normal cells, it selectively targets cancer cells, minimizing side effects.
- Exceptional Efficacy: It can conjugate over 1,000 antibodies onto a single nanoparticle, allowing for the creation of customized therapeutics loaded with various immune-oncology agents. This maximizes the effectiveness of immune-oncology drugs and blocks the immune evasion mechanisms of cancer cells.
- Outstanding Longevity: It has a high adhesive strength to subcutaneous tissues, allowing it to maintain therapeutic effects over an extended period after subcutaneous injection, inducing a sustained immune response against cancer cells.